June 17, 2026 · Form 4 insider transaction
Phillips Andrew John bought 22,195 shares of MoonLake Immunotherapeutics at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.